Trillium Therapeutics Equity 2025

Trillium Therapeutics Aktienanalyse

What does Trillium Therapeutics do?

Trillium Therapeutics Inc is a Canadian biotech company specializing in the development of cancer treatments. The company was founded in 2005 and is based in Mississauga, Ontario. Trillium Therapeutics is involved in various areas of research. One of its key focuses is the development of immunotherapies for cancer treatment. The company is working on the discovery and development of novel targeted immunotherapies that aim to specifically target tumors and utilize the body's immune system to fight cancer. Another focus of Trillium Therapeutics is the development of cancer drugs targeting specific gene mutations. These drugs are intended to inhibit or kill cancer cells by specifically targeting the genetically altered cells. Trillium Therapeutics is also involved in the discovery and development of drugs for the treatment of immuno-oncological diseases, which are diseases where the body's immune system fights against its own cells, such as autoimmune diseases. The business model of Trillium Therapeutics is based on the research and development of innovative cancer drugs. The company collaborates closely with leading cancer centers and clinics to identify and test new therapeutic approaches. Trillium Therapeutics has a number of products and therapies in development. One example is TTI-621, an immunotherapy that aims to recognize and kill tumor cells. TTI-621 is currently in clinical trials for the treatment of T-cell lymphomas and glioblastomas, a type of brain tumor, and has shown promising results. Another product that Trillium Therapeutics is working on is TTI-622. It is also an immunotherapy that focuses on inhibiting T-cells to support controlled tumor growth. TTI-622 is currently in clinical trials in patients with advanced cancer. The company is also working on a number of preclinical programs aimed at expanding treatment options for cancer patients. These programs target various biological targets, including immunomodulation, induction of apoptosis, and inhibition of DNA repair. Trillium Therapeutics has received several awards and recognitions in recent years, including inclusion in the Russell 3000 Index, being named the top biotechnology company on the BioCentury Future Leaders List, and being recognized as one of the top 10 most exciting biotech companies in Canada. Overall, Trillium Therapeutics is a leading biotech company focused on the development of innovative cancer therapies. The company is at the forefront of technology and collaborates closely with leading cancer centers and clinics to develop products that can improve the lives of cancer patients. Trillium Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Trillium Therapeutics's Equity

Trillium Therapeutics's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Trillium Therapeutics's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Trillium Therapeutics's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Trillium Therapeutics's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Trillium Therapeutics’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Trillium Therapeutics stock

What is the equity of Trillium Therapeutics this year?

Trillium Therapeutics has equity of 0 USD this year.

What was the equity of Trillium Therapeutics compared to the previous year?

The equity of Trillium Therapeutics has increased/decreased by 0% decreased compared to the previous year.

What impact does a high equity have on investors of Trillium Therapeutics?

A high equity is advantageous for investors of Trillium Therapeutics as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Trillium Therapeutics?

A low equity can be a risk for investors of Trillium Therapeutics, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Trillium Therapeutics affect the company?

An increase in equity of Trillium Therapeutics can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Trillium Therapeutics affect the company?

A reduction in equity of Trillium Therapeutics can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Trillium Therapeutics?

Some factors that can affect the equity of Trillium Therapeutics include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Trillium Therapeutics so important for investors?

The equity of Trillium Therapeutics is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Trillium Therapeutics take to change the equity?

To change equity, Trillium Therapeutics can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Trillium Therapeutics pay?

Over the past 12 months, Trillium Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Trillium Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Trillium Therapeutics?

The current dividend yield of Trillium Therapeutics is .

When does Trillium Therapeutics pay dividends?

Trillium Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Trillium Therapeutics?

Trillium Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Trillium Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Trillium Therapeutics located?

Trillium Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Trillium Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Trillium Therapeutics from 7/27/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/27/2025.

When did Trillium Therapeutics pay the last dividend?

The last dividend was paid out on 7/27/2025.

What was the dividend of Trillium Therapeutics in the year 2024?

In the year 2024, Trillium Therapeutics distributed 0 USD as dividends.

In which currency does Trillium Therapeutics pay out the dividend?

The dividends of Trillium Therapeutics are distributed in USD.